Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Esophageal cancer is a highly lethal malignancy, representing 5% of all cancer-related deaths. The two main subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). While most research has focused on ESCC, few studies have analyzed EAC for transcriptional signatures linked to diagnosis or prognosis. In this study, we utilized single-cell RNA sequencing and bulk RNA sequencing to identify specific immune cell types that contribute to anti-tumor responses, as well as differentially expressed genes (DEGs). We have characterized transcriptional signatures, validated against a wide cohort of TCGA patients, that are capable of predicting clinical outcomes and the prognosis of EAC post-surgery with efficacy comparable to the currently accepted prognostic factors. In conclusion, our findings provide insights into the immune landscape and therapeutic targets of EAC, proposing novel immunological biomarkers for predicting prognosis, aiding in patient stratification for post-surgical outcomes, follow-up, and personalized adjuvant therapy decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11311406 | PMC |
| http://dx.doi.org/10.3390/cancers16152748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrative GEO and Mendelian randomization analysis reveals transcriptomic and lipidomic features of esophageal adenocarcinoma.
Medicine (Baltimore)
August 2025
Department of Pathology, Affiliated Hospital 2 of Nantong University, Nantong, China.
Background: The incidence of esophageal adenocarcinoma (EA) has significantly increased in developed Western countries. Despite medical advancements, the prognosis remains poor, with a 5-year survival rate of less than 20%. By 2024, the global incidence is expected to reach 141,300 new cases annually, underscoring the urgent need to elucidate the mechanisms underlying EA pathogenesis to develop effective preventive and therapeutic strategies.
View Article and Find Full Text PDFNew Approaches to Screening for Barrett Esophagus.
Gastroenterol Hepatol (N Y)
June 2025
Division of Gastroenterology, Mayo Clinic, Jacksonville, Florida.
Current screening methods for Barrett esophagus (BE), the precursor to esophageal adenocarcinoma (EAC), are inadequate with less than one-third of screen-eligible patients currently undergoing screening. In addition to low screening rates, key issues include overemphasis on gastroesophageal reflux disease symptoms and lack of provider awareness, owing in part to heterogeneous guidelines. To address these challenges, several new approaches are being explored: swallowable cell collection devices, exhaled volatile organic compounds analysis, blood-based molecular biomarkers, microbiome analysis, and alternative visualization methods such as transnasal and capsule endos-copy.
View Article and Find Full Text PDFMulti-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.
Front Oncol
August 2025
Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA, United States.
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the early detection of esophageal cancer (EC), offering a minimally invasive means to assess tumor-derived genomic and epigenomic alterations. This review synthesizes current data on ctDNA biology, detection technologies, diagnostic performance, and clinical applicability in both esophageal adenocarcinoma and squamous cell carcinoma. We conducted a comprehensive literature review of PubMed-indexed studies on ctDNA in EC, emphasizing recent (January 1, 2019- December 31, 2024) findings, systematic reviews, and meta-analyses.
View Article and Find Full Text PDFStage IVA Esophageal Adenocarcinoma Diagnosed Post-Esophagectomy for End-Stage Achalasia.
Cureus
July 2025
Division of Digestive Diseases and Nutrition, Joy McCann Culverhouse Center for Swallowing Disorders, University of South Florida Morsani College of Medicine, Tampa, USA.
Achalasia is a disorder of unknown etiology that disrupts esophageal motility and esophagogastric junction outflow. Many long-term complications are associated with achalasia, including progression to megaesophagus and an increased risk for esophageal cancer. While current guidelines recommend against routine screening for cancer in patients with achalasia, many experts believe that routine endoscopic or radiographic screening at a yet-to-be-determined interval could provide essential data beyond evaluating for cancer.
View Article and Find Full Text PDFeQTL and multi-omics integration reveal PPIH as a prognostic and immunotherapeutic biomarker.
Front Immunol
September 2025
Medical Integration and Practice Center, Shandong University, Jinan, China.
Background: Malignant tumors remain a major threat to global human health. This study aimed to systematically integrate multi-omics data to identify a candidate gene with biomarker potential across diverse cancer types and to evaluate its possible clinical applications in oncology.
Methods: We first performed Mendelian randomization based on summary statistics to integrate blood expression quantitative trait loci data with genome-wide association study results from esophageal adenocarcinoma, stomach cancer, and clear cell renal cell carcinoma.